Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis

Trial Profile

Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2019

At a glance

  • Drugs Octocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 19 Jun 2019 Status changed from active, no longer recruiting to completed.
    • 20 May 2019 Planned End Date changed from 30 Apr 2019 to 31 May 2019.
    • 12 Apr 2019 Planned End Date changed from 29 Mar 2019 to 30 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top